Participant flow - ANZCTR
Participant flow2. Baseline characteristicsProvide a table of baseline demographic and clinical characteristics (including important pre-intervention prognostic factors) for each study group.Table SEQ Table \* ARABIC 1. Bacterial prevalence at the baseline visit across the three treatment groupsBacterial SpeciesAll Samples (n = 71)CPP-ACP(n = 22)All-in-One(n = 23)Control(n = 26)P-valueActinomyces gerensceriae70 (99%)21 (96)23 (100%)26 (100%)0.323Corynebacterium durum70 (99%)21 (96)23 (100%)26 (100%)0.323Lactobacillus gasseri13 (18%)2 (9%)4 (17%)7 (27%)0.279Neisseria flavescens63 (89%)19 (86%)22 (96%)22 (85%)0.435Provotella denticola56 (79%)17 (77%)18 (78%)21 (81%)0.954Rothia aeria/dentocariosa71 (100%)22 (100%)23 (100%)26 (100%)δStreptococcus mitis/oralis71 (100%)22 (100%)23 (100%)26 (100%)δStreptococcus mutans54 (76%)16 (73%)18 (78%)20 (77%)0.902Streptococcus parasanguinis5 (7%)0 (0%)1 (4%)4 (15%).096Streptococcus salivarius/ thermophilus71 (100%)22 (100%)23 (100%)26 (100%)δStreptococcus sanguinis71 (100%)22 (100%)23 (100%)26 (100%)δStreptococcus sobrinus2 (2.8%)0 (0%)0 (0%)2 (8%)0.168Scardovia wiggsiae42 (59%)13 (59%)13 (57%)16 (62%)0.938Veillonella parvula71 (100%)22 (100%)23 (100%)26 (100%)δBaseline prevalence data showing number of samples in which the bacterial species was detected and values in brackets representing % prevalence. No significant differences between the treatment groups at the baseline visit (P > 0.05; chi-square test). δ: no statistics computed because bacterial prevalence was a constant.Outcome measuresTable 2. Fold change in bacterial loads from baseline to recall visit with pairwise treatment group comparisonsTreatment GroupsP-valuesBacterial SpeciesCPP-ACPAll-in-OneControlCPP-ACP versusControlAll-in-OneVersusControlCPP-ACP versusAll-in-OneActinomyces gerensceriae0.33 ± 0.120.47 ± 0.17 0.85 ± 0.170.2810.8161.00Corynebacterium durum14.45 ± 0.176.61 ± 0.131.92 ± 0.070.007*0.2070.579Lactobacillus gasseri0.94 ± 0.200.75 ± 0.080.95 ± 0.271.001.001.00Neisseria flavescens2.05 ± 0.0912.27 ± 0.02 0.64 ± 0.080.5710.003*0.158Provotella denticola2.18 ± 0.021.89 ± 0.044.74 ± 0.051.001.001.00Rothia aeria/dentocariosa0.97 ± 0.241.65 ± 0.100.54 ± 0.390.6640.0600.842Streptococcus mitis/oralis0.84 ± 0.150.98 ± 0.090.65 ± 0.201.001.001.00Streptococcus mutans0.52 ± 0.150.23 ± 0.072.51 ± 0.200.032*< 0.001*0.555Streptococcus parasanguinis0.56 ± 0.480.40 ± 0.110.37 ± 0.061.001.001.00Streptococcus salivarius0.67 ± 0.140.57 ± 0.181.21 ± 0.200.7480.4261.00Streptococcus sanguinis2.92 ± 0.263.44 ± 0.240.46 ± 0.29< 0.001*< 0.001*1.00Streptococcus sobrinus0.61 ± 0.490.60 ± 0.300.72 ± 0.271.001.001.00Scardovia wiggsiae0.57 ± 0.071.01 ± 0.091.52 ± 0.070.5701.001.00Veillonella parvula0.31 ± 0.170.11 ± 0.091.10 ± 0.300.061< 0.001*0.213Fold change values (mean ± S.D) for each bacterial species in the CPP-ACP group (n = 22), All-in-One group (n = 23) and control group (n = 26). Ratio below 1 indicates lower relative abundance; a ratio above 1 indicates higher relative abundance. Comparison for all pairs of treatment groups was using the Bonferroni post hoc test and * indicates where significant differences were found between the interventional group and the control group (P < 0.05). No differences were found between the two interventional groups for any bacterial species (P > 0.05).Figure 1 (A and B). Fold change in relative bacterial abundance from baseline to recall visit.* indicates significant differences using the one-way ANOVA and Simes adjustment for the multiple bacterial comparisons.4. Adverse events/harmsNO adverse effects or harms were reported by any of the trial participants in any of the three treatment groups. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- filmarray blood culture identification panel testing
- title of smi goes here
- participant flow anzctr
- medical distributor association imco inc
- molecular characterization of multi drug
- gram negative oxoid
- australian public assessment for besifloxacin hydrochloride
- communicable diseases intelligence 2020 bacterial ocular
Related searches
- central dogma flow chart
- vanguard retirement plan participant website
- john hancock 401k participant website
- participant modeling definition psychology
- 401 k participant loan rules
- participant loan fund
- deemed distributions of participant loans
- empower retirement 401k participant loan
- start now participant workbook
- all of us participant portal
- participant fee disclosure notice
- annual participant recordkeeping fees o